Grafilo v. Wolfsohn

CourtCalifornia Court of Appeal
DecidedApril 2, 2019
DocketB287080
StatusPublished

This text of Grafilo v. Wolfsohn (Grafilo v. Wolfsohn) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Grafilo v. Wolfsohn, (Cal. Ct. App. 2019).

Opinion

Filed 4/2/19 CERTIFIED FOR PUBLICATION

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA

SECOND APPELLATE DISTRICT

DIVISION ONE

DEAN GRAFILO, as Director, etc., B287080 Plaintiff and Respondent, (Los Angeles County v. Super. Ct. No. BS171234) MARC DAVID WOLFSOHN, Defendant and Appellant;

KIMBERLY KIRCHMEYER, as Executive Director, etc., Real Party in Interest and Respondent.

APPEAL from an order of the Superior Court of Los Angeles County, Howard L. Halm, Judge. Reversed. Bonne, Bridges, Mueller, O’Keefe & Nichols, and Joel Bruce Douglas for Defendant and Appellant. Xavier Becerra, Attorney General, Gloria L. Castro, Assistant Attorney General, Judith T. Alvarado, and Christine R. Friar, Deputy Attorneys General, for Plaintiff and Respondent Dean Grafilo, Director of the Department of Consumer Affairs, and Real Party in Interest and Respondent Kimberly Kirchmeyer, Executive Director of the Medical Board of California. Marc David Wolfsohn, M.D., appeals from an order compelling him to produce the medical records of five of his patients pursuant to a subpoena issued by an investigator with the Medical Board of California (Medical Board), a unit of the Department of Consumer Affairs (DCA). We agree with Wolfsohn that the DCA did not establish good cause for the subpoena and, therefore, reverse.

FACTUAL AND PROCEDURAL SUMMARY A. Background Wolfsohn is a physician specializing in pain management. He has been licensed by the Medical Board to practice medicine since 1977. In December 2014, the Medical Board received a report from a law enforcement officer that Wolfsohn may be overprescribing controlled substances to patients. The Medical Board opened an investigation and obtained from the Controlled Substance Utilization Review and Evaluation System1 (“CURES”) a report of Wolfsohn’s history of prescribing controlled substances for the period between January 30, 2014 and January 30, 2015. Dr. Shoaib Naqvi is a medical consultant for the DCA with the “responsibility to maintain familiarity with the standard of medical practice in the State of California.” Naqvi reviewed the CURES report and identified five patients (J.A., R.G., V.J., J.R. and V.H.; collectively, the patients) to whom, in Naqvi’s opinion,

1 CURES is a prescription drug monitoring program that includes information regarding prescriptions for certain controlled substances. (Health & Saf. Code, § 11165, subds. (a) & (d); Lewis v. Superior Court (2017) 3 Cal.5th 561, 565 (Lewis).)

2 Wolfsohn “prescribed controlled substances in a manner that appeared to be inconsistent with the standard of care for prescribing those drugs.” According to Naqvi, the “only way to determine whether Wolfsohn properly and safely administered any of these controlled substances to the five patients . . . is to obtain and review the complete and accurate medical records of the five patients.” In early September 2016, the DCA issued and served on Wolfsohn an investigational subpoena duces tecum pursuant to Government Code section 11181. The subpoena commanded Wolfsohn to produce “the complete medical record” for each of the patients for the period January 1, 2014 through March 31, 2016. The document production was set to take place before DCA investigator Tracy Tu on September 26, 2016. It does not appear from our record that the DCA provided a copy of the subpoena to the patients or otherwise notified them that it was seeking their medical records from Wolfsohn prior to the stated production date. On September 20, 2016, Wolfsohn’s attorney delivered a letter to Tu stating, “[W]e contacted the patients,” who “confirmed that they do not want [Tu] or the Medical Board to have access to their confidential medical information.” Accordingly, Wolfsohn would “refuse to comply with the subpoena duces tecum and assert [the patients’] constitutional privacy rights and statutory privilege under the doctor/patient privilege, if not the psychotherapist/patient privilege.” Wolfsohn did not appear or produce the requested medical records pursuant to the subpoena. About five months later, on February 23, 2017, Medical Board investigator Tu sent by regular and certified mail a letter to the patients stating that the DCA’s division of investigation “is attempting to obtain your medical records from Marc

3 Wolfsohn, M.D. via service of a subpoena” (capitalization omitted) that “was served on 09/09/16 compelling the production of your records by 09/26/16. [¶] If you have an objection to the use of your records in this process, you may wish to consult an attorney to discuss your options.” Enclosed with the letter is a copy of the subpoena served on Wolfsohn and a document titled “Notice to Medical Consumers.” (Capitalization omitted.) This document describes the investigatory role of the DCA’s division of investigation, and states that DCA “[i]nvestigators and medical consultants read and evaluate the medical records of patients who were treated by those whose practices have come under question.” Although “patient records are kept confidential . . . during the investigation,” the “records may become part of the official proceeding record. . . . [¶] If you have an objection to the use of your records in this process, you may wish to consult an attorney to discuss your options.” On March 12, 2017, Wolfsohn’s attorney sent a letter to Tu stating that V.H., who had previously objected to the request for her medical records, “continues to protest this unwarranted intrusion into her privacy.” Our record does not reveal whether any other patients received the DCA’s letter or whether the DCA undertook other efforts to notify the patients.

B. DCA’s Petition to Compel Compliance with Subpoena On October 30, 2017, the Attorney General, on behalf of the DCA, filed a petition in Los Angeles County Superior Court for an order compelling Wolfsohn to comply with the subpoena. The petition names Wolfsohn as the sole respondent and names Kimberly Kirchmeyer, in her capacity as the executive director of the Medical Board, as the real party in interest.

4 The petition was supported by Naqvi’s declaration. Naqvi described generally the various statutory classes, or schedules, of controlled substances (see Health & Saf. Code, §§ 11054–11058); referred to a measurement known as “morphine equivalent dosing” (MED), which is used to compare different pain relieving drugs; and, with respect to particular drugs, identified the drug’s class, its use in treatment, and its potential adverse consequences. Naqvi also opined as to actions physicians must take to comply with the standard of care when prescribing controlled substances. These include conducting an appropriate examination of the patient, documenting the diagnosis underlying the prescription, obtaining informed consent regarding potential risks (which Naqvi stated is required when the MED value exceeds 100), and evaluating “any co-morbid conditions that could be worsened by the use of [the] drug.” According to Naqvi, the CURES report for Wolfsohn revealed that each of the patients whose records are sought in the subpoena, had “prescription patterns that, in the absence of any other information, appear to represent concerning departures from the standard of care for prescribing these controlled substances.” He described the drugs that (according to the CURES report) Wolfsohn prescribed to each patient, the amount of each prescribed drug, and the frequency of the prescriptions fulfilled. Based on this data, he estimated a range of MED values for the patients ranging from 80 to 300.2 Naqvi does not opine that the data or the MED level indicated by the CURES report constitutes a violation of the Medical

2 The DCA did not offer the CURES report in support of its petition and it is not included in our record.

5 Practices Act or breaches a standard of care.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hill v. National Collegiate Athletic Assn.
865 P.2d 633 (California Supreme Court, 1994)
Board of Medical Quality Assurance v. Gherardini
93 Cal. App. 3d 669 (California Court of Appeal, 1979)
Bearman v. Superior Court
11 Cal. Rptr. 3d 644 (California Court of Appeal, 2004)
Lantz v. Superior Court
28 Cal. App. 4th 1839 (California Court of Appeal, 1994)
People v. Martinez
105 Cal. Rptr. 2d 841 (California Court of Appeal, 2001)
Medical Bd. of Calif. v. Chiarottino
225 Cal. App. 4th 623 (California Court of Appeal, 2014)
Fett v. Medical Board of California
245 Cal. App. 4th 211 (California Court of Appeal, 2016)
Kirchmeyer v. Phillips
245 Cal. App. 4th 1394 (California Court of Appeal, 2016)
Cross v. Superior Court of Los Angeles County
11 Cal. App. 5th 305 (California Court of Appeal, 2017)
Williams v. Superior Court of L. A. Cnty.
398 P.3d 69 (California Supreme Court, 2017)
Lewis v. Superior Court of L. A. Cnty.
397 P.3d 1011 (California Supreme Court, 2017)
Arnett v. Dal Cielo
923 P.2d 1 (California Supreme Court, 1996)
Grafilo v. Cohanshohet
243 Cal. Rptr. 3d 807 (California Court of Appeals, 5th District, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Grafilo v. Wolfsohn, Counsel Stack Legal Research, https://law.counselstack.com/opinion/grafilo-v-wolfsohn-calctapp-2019.